Last Updated : June 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Epidiolex | cannabidiol | Dravet Syndrome (DS) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Epkinly | epcoritamab | Relapsed or refractory diffuse large B-cell lymphoma | Time-limited reimbursement recommendation | Active | ||
| Erbitux | Cetuximab | Cancelled | ||||
| Erbitux | Cetuximab | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
| Erelzi | Etanercept | Rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Erivedge | Vismodegib | Basal Cell Carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Erleada | Apalutamide | metastatic castration-sensitive prostate cancer (mCSPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Erleada | Apalutamide | non-metastatic castrate resistant prostate cancer (nm-CRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Esbriet | Pirfenidone | Idiopathic pulmonary fibrosis | Do not list | Complete | ||
| Esbriet | Pirfenidone | Idiopathic pulmonary fibrosis | List with criteria/condition | Complete | ||
| Eucrisa | crisaborole | atopic dermatitis | Do not reimburse | Complete | ||
| Evenity | romosozumab | Osteoporosis, postmenopausal women | Reimburse with clinical criteria and/or conditions | Complete | ||
| Evkeeza | evinacumab | Homozygous familial hypercholesterolemia (HoFH) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Evra | Norgelestromin/ethinyl estradiol | Contraceptive, patch | Do not list | Complete | ||
| Evrysdi | risdiplam | Spinal muscular atrophy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Exelon Patch | Rivastigmine | Dementia (Alzheimer's type) | Do not list | Complete | ||
| Exjade | Deferasirox | Iron overload | List with clinical criteria and/or conditions | Complete | ||
| Eylea | Aflibercept | Macular edema, branch retinal vein occlusion | Reimburse with clinical criteria and/or conditions | Complete | ||
| Eylea | Aflibercept | Macular degeneration, age-related | List with criteria/condition | Complete | ||
| Eylea | Aflibercept | Macular edema, diabetic | List with clinical criteria and/or conditions | Complete | ||
| Eylea | Aflibercept | Macular edema, central retinal vein occlusion | List with clinical criteria and/or conditions | Complete | ||
| Eylea HD | aflibercept 8mg/0.07mL | macular degeneration, age related | Reimburse with clinical criteria and/or conditions | Active | ||
| Eylea HD | aflibercept 8mg/0.07mL | diabetic macular edema | Reimburse with clinical criteria and/or conditions | Active | ||
| Fabrazyme | Agalsidase beta | Fabry Disease | Do not list | Complete | ||
| Fabrazyme | Agalsidase beta | Fabry Disease | Do not list | Complete |
Last Updated : June 30, 2024